Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss can be caused by cancer, treatments, or skin conditions, and trichoscopy helps diagnose it.

DHA derivatives, especially didocosahexaenoin, effectively kill prostate cancer cells and may offer a safer cancer treatment option.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

About 22% of cancer patients had skin-related side effects from chemotherapy, but these were usually not severe enough to halt treatment.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

Deep phenotyping helps distinguish between xeroderma pigmentosum and trichothiodystrophy, aiding in diagnosis and treatment.

Dutasteride works better than finasteride for preventing and treating prostate cancer.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Combining topical delgocitinib with a 308-nm excimer laser can effectively treat severe alopecia areata and vitiligo.

Cancer treatments often cause hair loss, and more research is needed to prevent and treat it.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

Dauricine may help treat certain brain cancers by reducing cancer cell growth and promoting cell death.

A man developed skin lesions as a side effect of a gamma secretase inhibitor used for treating a tumor.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Preventing and managing skin issues from cancer treatment is crucial, especially in high UV areas like Australia and New Zealand.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Ocrelizumab may cause total body hair loss in some patients.

Ixekizumab has known and some unexpected side effects.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Certain cancer drugs can cause skin issues like rashes and itching.

Upadacitinib improved multiple immune-related conditions in one patient.

Targeted cancer therapies often cause skin side effects, needing dermatologist care.

Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.